Abel Hall LLC
AXSM icon

Abel Hall LLC’s Axsome Therapeutics AXSM Stock Holding History

Abel Hall LLC’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$241K Sell
1,309
-288
-18% -$62.7K 0.04% 557
2026
Q2 		$391K Buy
1,597
+394
+33% +$85.4K 0.07% 343
2026
Q1 		$203K Buy
1,203
+34
+3% +$5.87K 0.04% 621
2025
Q4 		$214K Buy
+1,169
New +$163K 0.05% 508

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Iridian Asset Management
Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return
Baldwin Wealth Partners
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return
Washington Trust Advisors
Washington Trust Advisors Wellesley, Massachusetts $1.4B AUM 26.88% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Stanley-Laman Group
Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Abel Hall LLC's AXSM Position: Q3 2026 in Review

Abel Hall LLC reduced its Axsome Therapeutics (AXSM) stake by 18% in Q3 2026, selling an estimated $62.7K and leaving 1,309 shares worth $241K. The position accounts for 0.04% of the portfolio, ranked #557.

Abel Hall LLC first reported a position in AXSM in Q4 2025 and has held it in 4 quarters since. The position peaked at $391K in Q2 2026. 114 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Abel Hall LLC held 1,309 shares of Axsome Therapeutics worth $241K as of Q3 2026.
  • Abel Hall LLC sold 288 Axsome Therapeutics shares in Q3 2026, an estimated $62.7K.
  • Axsome Therapeutics made up 0.04% of Abel Hall LLC's portfolio in Q3 2026, its #557 holding.
  • Abel Hall LLC first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Abel Hall LLC's Axsome Therapeutics position peaked at $391K in Q2 2026.
  • 114 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.